These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29438592)

  • 41. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
    Oefelein M
    J Urol; 2003 Jan; 169(1):251-5. PubMed ID: 12478147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
    Gu C; Wang Z; Lin T; Liu Z; Han W; Zhang X; Liang C; Liu H; Yu Y; Xu Z; Liu S; Wang J; Jia L; Yao X; Liao W; Fu C; Tan Z; He G; Zhu G; Fan R; Yang W; Chen X; Liu Z; Zhong L; Shi B; Ding D; Chen S; Wei J; Yao X; Chen M; Lu Z; Xie Q; Hu Z; Wang Y; Guo H; Fan T; Liang Z; Chen P; Wang W; Xu T; Li C; Xing J; Liao H; He D; Wu Z; Yu J; Feng Z; Yang M; Dou Q; Zeng Q; Li Y; Gou X; Zhou G; Wang X; Zhu R; Zhang Z; Zhang B; Tan W; Qu X; Sun H; Gan T; Ye D
    Chin Med J (Engl); 2023 May; 136(10):1207-1215. PubMed ID: 37010251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
    Boccon-Gibod L; Iversen P; Persson BE
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
    Kienle E; Lübben G
    Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
    Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
    Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
    Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
    Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
    Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
    Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
    Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
    Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
    Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
    Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
    Chang JI; Bucci J
    J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.
    Ozono S; Tsukamoto T; Naito S; Horie S; Ohashi Y; Uemura H; Yokomizo Y; Fukasawa S; Kusuoka H; Akazawa R; Saito M; Akaza H
    Cancer Sci; 2018 Jun; 109(6):1920-1929. PubMed ID: 29624800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy.
    DeJongh J; Ahsman M; Snelder N
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):465-477. PubMed ID: 33538922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.